The Process Is the Point: Why Pharma’s Obsession with Automation is Missing the Mark

For over a decade, the pharmaceutical industry has been chasing the ghost of digital transformation. We’ve seen billion-dollar initiatives promised to revolutionize R&D, only to result in more administrative overhead and fragmented workflows. Poonam Rihel, a seasoned enterprise leader in the R&D space, has seen this cycle play out firsthand. Her diagnosis is as sharp as it is sobering: organizations are repeatedly layering expensive technology on top of broken processes instead of fixing the foundation first. As we enter the era of agentic AI and automated regulatory writing, Rihel warns that the industry is at risk of making the exact same mistakes again.

The Intersection of Science and Execution

Clinical reporting isn't just a back-office task; it is perhaps the most consequential intersection in the entire drug development lifecycle. This is where scientific discovery meets operational execution and where that execution must satisfy the rigorous demands of global regulators. If this stage falters, submissions are delayed, and life-saving treatments stay on the shelf. If done correctly, it has the power to compress timelines across an entire portfolio. Rihel’s career has been dedicated to this R&D value chain, focusing on medical and regulatory writing not just as a document-production exercise, but as an exercise in organizational logic. As AI begins to redefine what it means to "write" in a highly regulated space, her insights provide a roadmap for true transformation.

Why We Must Rebuild Before We Automate

The temptation in any large enterprise is to find a digital "silver bullet." We buy a new system, plug it in, and expect efficiency to follow. However, Rihel notes that this often creates "pseudo-work"—new tasks that exist only to serve the software rather than the science. When you move an inefficient flow into a sophisticated system, you don't solve the problem; you just get a different set of problems. The key, according to Rihel, is reimagining the underlying layer: defining who is responsible, what the scientific intent is, and standardizing the approach before the first line of code is written for an automation tool. It’s about scientific clarity over digital vanity.

The Myth of the 'Unique' Report

A common hurdle in large-scale transformation is the belief that certain projects are simply too unique to be standardized. Rihel is quick to debunk this. While variations exist, the idea that a study report is a total exception to the rule is usually a misunderstanding of what standardization actually means. It isn’t about creating a rigid cage; it’s about building a frame. Standardization provides the guardrails that allow for innovation where it actually matters. By reverse-engineering successful submissions and comparing measurable impacts, Rihel’s teams have shown that focusing on standardized sections allows writers to spend more time on the high-impact areas that require deep scientific nuance.

Winning Hearts and Minds in Change Management

Transforming a legacy pharma organization is a Herculean task that leaves what Rihel calls "battle scars." There are two schools of thought: the forced change and the enterprise-led change. While both can work, the latter is far more sustainable. Rihel advocates for a "build it and show them" approach. When people see a re-engineered process that fundamentally improves how they interact with their work, the proof is in the pudding. But that’s only the start. Success requires relentless communication, standing one's ground, and convincing stakeholders that the change is a value proposition for them, not just a mandate from the top.

AI as an Amplifier, Not a Replacement

One of the biggest fears in the industry is that AI will eventually replace the deep expertise of medical and regulatory writers. Rihel is clear on this: the human stays in the loop. In a regulated environment, a human must always be the one to make the final decision and press the button. The goal isn't to have fewer writers; it’s to amplify their individual impact. AI can handle the heavy lifting of data pulling and initial drafting, but the "scientific red thread," the strategic nuances, and the narrative flow still require human intelligence. The future of the role involves shifting from manual task execution to high-level facilitation and strategic reasoning.

Building a Defensible AI Audit Trail

As AI integration deepens, the industry faces a new challenge: auditability. How do you prove to a regulator exactly how a conclusion was reached if an LLM was involved? Rihel emphasizes that this is an ongoing work in progress. A defensible AI audit trail must break down the thinking process—identifying where data was pulled from, what context was applied, which models were used, and exactly where a human signed off on the decision. The "sweet spot" lies in using AI to create a draft while maintaining the same rigorous human diligence that has always been required in clinical reporting. Ultimately, the expertise of the writer—their ability to see the story within the data—remains the most valuable asset in the room.